Clinical Trial Update: Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial of brostallicin for recurrent or refractory multiple myeloma and related plasma cell neoplasms has completed enrollment/status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• Brostallicin (brostallicin)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 1, Phase 2 | Status: COMPLETED